FORMULATION AND EVALUATION OF LIQUISOLID COMPACTS OF LORNOXICAM

Asma A. Mokashi; SNEHALATA L. GAIKWAD

doi:10.22159/ijpps.2019v11i6.28328

Authors

Asma A. Mokashi M.C.E Society’s Allana College of Pharmacy, Azam Campus, Camp, Pune (MS) India
SNEHALATA L. GAIKWAD Quality Assurance Executive, Encube Ethicals Pvt. Ltd., Mumbai (MS) India

DOI:

https://doi.org/10.22159/ijpps.2019v11i6.28328

Keywords:

Lornoxicam, Liquisolid compact, In-vitro dissolution study, Solubility

Abstract

Objective: Objective of the present investigation was to enhance the solubility and dissolution rate of poorly water-soluble drug lornoxicam using liquisolid technique with comparative determination of in vitro release profile of liquisolid compacts and conventional formulation of lornoxicam.

Methods: Formulation was prepared by a liquisolid technique using different drug concentration in a liquid vehicle and different carrier/coating ratio. Prepared liquisolid compact was evaluated for Fourier transform infrared (FTIR) spectra analysis, differential scanning calorimetry (DSC), X-ray diffraction (P-XRD), scanning electron microscopy (SEM) and in vitro dissolution study.

Results: The result showed that liquisolid compacts of lornoxicam displayed significantly higher drug release rate as compared to pure drug and conventional tablet prepared. The results of both DSC and X-ray crystallography indicated loss of crystallinity of the drug upon formulated into the liquisolid compact.

Conclusion: Dissolution rate of the drug from liquisolid compacts was affected by changing the drug concentration and excipient ratio. The liquisolid technique appeared to be a promising approach for improving the dissolution of poorly soluble drug lornoxicam.

Downloads

Download data is not yet available.

References

Charman SA, Charman WN. Oral modified release delivery systems. In: Rathbone MJ, Hadgraftb J, Roberts MS. Editors. Modified release drug delivery technology. New York: Marcel Dekker Inc; 2003.

Fahmy RH, Kassem MA. Enhancement of famotidine dissolution rate through liquisolid tablets formulation: in vitro and in vivo evaluation. Eur J Pharm Biopharm 2008;69:993-1003.

Spireas SS. Liquisolid systems and methods of preparing same. United State Patent no 5800834; 1998.

Panda S, Varaprasad R, Priyanka K, Swain R. Liquisolid technique: a novel approach for dosage form design. Int J Appl Pharm 2017;9:8-14.

Elkordy AA, Tan XN, Ebtessam EA. Spironolactone release from liquisolid formulation prepared with CapryolTM 90, Solutol® HS-15, Kollicoat® SR 30 D as non-volatile liquid vehicles. Eur J Pharm Biopharm 2013;83:203-23.

Spireas S, Sadu S. Enhancement of prednisolone dissolution properties using liquisolid compacts. Int J Pharm 1998;166:177-88.

Louis D, Soliman II, Tayel SA. Improvement of dissolution properties of carbamazepine through application of the liquisolid tablet technique. Eur J Pharm Biopharm 2008; 69:342-7.

Sanjaymitra PV, Ganesh GN. Dissolution and solubility enhancement strategies: current and novel prospectives. J Crit Rev 2018;5:1-10.

Banker GS, Anderson NR. Tablets. In: Lachman L, Lieberman HA. editors. The theory and practice of industrial pharmacy. 2nd ed. Noida: India Binding House; 2009. p. 293-45.

Noyes AA, Whitney WR. The rate of dissolution of solid substances in their own solutions. J Am Chem Soc 1897;19:930–4.

Khan A, Agrawal S. Formulation and evaluation of lumefantrine capsule prepared by using the liquisolid technique. Int J Curr Pharm Res 2018;10:43-50.

Hentzschel CM, Alnaief M, Smirnova I, Sakmann A. Enhancement of griseofulvin release from liquisolid compacts. Eur J Pharm Biopharm 2012;80:130-5.